Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

JANX

NASDAQ

Janux Therapeutics (JANX)

16 USD +1.04% vs prior close
Janux Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
978.9M USD
Revenue, year to Dec 2025
10.0M USD
EPS, diluted, year to Dec 2025
−1.83 USD
52-week range
12.19 USD – 35 USD
Avg volume
267.2K

as of Jul 17, 2026

Have Janux Therapeutics (JANX) insiders bought or sold shares recently?

JANX's newest Form 4 filing is dated 31 July 2026: none in the last 90 days.

Form 4

Have Janux Therapeutics (JANX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
02 Jun 2026Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrSell4,05957K USD
11 May 2026Dobek MariaVice President, AccountingSell2,03829K USD
02 Jan 2026Campbell David AlanPresident and CEOSell8,072111K USD
02 Jan 2026DiRaimondo ThomasChief Scientific OfficerSell2,50534K USD
02 Jan 2026Dobek MariaVice President, AccountingSell1,46220K USD
02 Jan 2026Meyer Andrew HollmanChief Business OfficerSell1,87926K USD
02 Jan 2026Winter Charles M.Chief Technical OfficerSell2,40133K USD
02 Jan 2026McIver ZachariahChief Medical OfficerSell2,71437K USD
01 Dec 2025Meyer Andrew HollmanChief Business OfficerSell3,333110K USD
14 Nov 2025Meyer Andrew HollmanChief Business OfficerSell3,333100K USD
28 Oct 2025Meyer Andrew HollmanChief Business OfficerSell16,665501K USD
Sold11 open-market sales48,461$1.06M
19 other filings: grants, exercises, tax withholding and transfers, not trades
Have Janux Therapeutics (JANX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
31 Jul 2026Campbell David AlanPresident and CEOGift123,840
08 Jul 2026Campbell David AlanPresident and CEOOption exercise7,00029K USD
11 Jun 2026Barrett Ronald WDirectorAward5,500
11 Jun 2026CAPPS VICKIE LDirectorAward5,500
11 Jun 2026DOBMEIER ERICDirectorAward5,500
11 Jun 2026Hernday NatashaDirectorAward5,500
11 Jun 2026RA CAPITAL MANAGEMENT, L.P.DirectorAward5,500
11 Jun 2026Kung WinstonDirectorAward5,500
11 Jun 2026Simson JakeDirectorAward5,500
02 Feb 2026Go WilliamChief Medical OfficerAward44,000
02 Jan 2026Campbell David AlanPresident and CEOAward96,600
02 Jan 2026DiRaimondo ThomasChief Scientific OfficerAward31,400

Showing the 12 most recent of 19 compensation filings in this window. The figures above count all of them.

Which funds hold Janux Therapeutics (JANX)?

10 of the 45 institutional funds we track reported a Janux Therapeutics position for the quarter ended 30 Jun 2026 — a combined 101.9M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Janux Therapeutics (JANX)?
FundPositionSharesValueShares q/q
Point72 Asset ManagementAdded1,993,83730.6M USD+72.5%
Two Sigma InvestmentsAdded1,207,25018.5M USD+939.8%
Citadel AdvisorsAdded1,200,73718.4M USD+240.9%
D. E. Shaw & Co.Added1,096,50916.8M USD+1,014.4%
Millennium ManagementAdded504,5447.7M USD+30.4%
Man GroupTrimmed248,8013.8M USD−27.5%
Balyasny Asset ManagementTrimmed211,6353.3M USD−80.6%
AQR Capital ManagementNew position108,0771.7M USD
Marshall WaceNew position32,734503K USD
Tudor Investment CorpHeld (±25%)28,070431K USD−5.5%

What has been filed or recorded for Janux Therapeutics (JANX)?

The filings we hold for Janux Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Janux Therapeutics (JANX)?
And
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.34 USD
30 Sep 2026FinancialsTotal assets983.7M USDat period end
30 Sep 2026FinancialsTotal equity911.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.35 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.39 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.83 USD
31 Dec 2025FinancialsRevenue10.0M USDfiscal year
31 Dec 2025FinancialsNet income−113.6M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.83 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.39 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.55 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.38 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.28 USD

What do people ask about Janux Therapeutics (JANX)?

From live data
What is Janux Therapeutics’ market cap?978.9M

Janux Therapeutics is worth 978.9M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Janux Therapeutics’ revenue?10.0M

Janux Therapeutics reported revenue of 10.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Janux Therapeutics insiders bought or sold shares recently?

No Janux Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 31 Jul 2026 (SEC Form 4). See Insiders

Which funds own Janux Therapeutics?10 of 45

10 of the 45 funds we track reported a Janux Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Point72 Asset Management, Two Sigma Investments and Citadel Advisors. See Funds

When did Janux Therapeutics last report earnings?−0.34

Janux Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.34 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings